Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence

Miguel Muñoz, Marisa Rosso, Fernando Casinello, Rafael Coveñas

► To cite this version:

Miguel Muñoz, Marisa Rosso, Fernando Casinello, Rafael Coveñas. Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence. Breast Cancer Research and Treatment, 2010, 122 (2), pp.601-603. 10.1007/s10549-010-0850-y . hal-00535449

HAL Id: hal-00535449

<https://hal.science/hal-00535449>

Submitted on 11 Nov 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence

Miguel Muñoz · Marisa Rosso · Fernando Casinello ·
Rafael Coveñas

Received: 20 January 2010 / Accepted: 13 March 2010 / Published online: 24 March 2010
© Springer Science+Business Media, LLC. 2010

Aristotle's *Techné* Concept Knowledge and understanding belong to art (*techné*) rather than to experience, and we suppose artists to be wiser than men of experience; and this because the former know the cause, but the latter do not. For men of experience know that the thing is so, but do not know why, while the others know the 'why' and the cause.

(*Metaphysics* by Aristotle. Book I)

In a retrospective study, Exadaktylos et al. [1] reported a beneficial relationship between paravertebral block and cancer recurrence in women undergoing mastectomy and axillary clearance for breast cancer. In fact, these authors concluded that "breast cancer patients undergoing surgery with paravertebral anesthesia and analgesia combined with general anesthesia have a lower incidence of cancer recurrence or metastasis during the initial years of follow-up than patients undergoing surgery with general anesthesia and patient-controlled morphine analgesia" [1]. These authors speculated that regional anesthesia might attenuate

the perioperative factors that enhance tumor growth and spreading [1]. In this sense, regional anesthesia may help to maintain normal perioperative immune function by attenuating the surgical stress response by blocking noxious inputs mediated by substance P [2]. It is known that the stress response induces an inhibition of the immune function (i.e., there is a marked attenuation of natural killer cells, these cells being involved in preventing tumor dissemination) [3]. Paravertebral anesthesia also spares patients from postoperative opioids (e.g., morphine), which inhibit both cellular and humoral immune function [4, 5]; in addition, it is known that morphine exerts a proangiogenic effect [6]. In sum, the authors surmised that regional anesthesia and analgesia may help to preserve immune function by attenuating the surgical stress response and diminishing the need for opioids. However, until now the underlying mechanisms remain unknown.

The reason for this letter is to provide additional data that could support and explain the relationship between regional anesthesia, analgesia, and the recurrence of cancer. Many reports have clearly established an overexpression of neurokinin-1 (NK-1) receptors in tumor cells and others have reported the roles in which substance P (SP) is involved [7]. Summing up these investigations, it could be stated that:

1. SP, after binding to the NK-1 receptor, is involved in pain transmission and in neurogenic inflammation. Regarding pain transmission, both the neuropeptide and NK-1 receptors are located in the dorsal horn of the spinal cord. Noxious stimuli enhance SP release from C-fibers and then SP depolarizes dorsal horn neurons in a similar manner to when electrical stimulation of C-fibers is carried out. It is known that both responses are blocked by NK-1 receptor antagonists. SP is a pain

M. Muñoz · M. Rosso
Research Laboratory on Neuropeptides, Virgen del Rocío
University Hospital, Sevilla, Spain

F. Casinello
Fundación Jiménez Díaz, Madrid, Spain

R. Coveñas
Laboratory of Neuroanatomy of the Peptidergic Systems
(Lab. 14), Institute of Neurosciences of Castilla y León
(INCYL), Salamanca, Spain

M. Muñoz (✉)
Hospital Infantil Virgen del Rocío, Unidad de Cuidados
Intensivos Pediátricos, Av. Manuel Siurot s/n,
41013 Sevilla, Spain
e-mail: mmunoz@cica.es

neurotransmitter, and SP receptor antagonists, synonymous of NK-1 receptor antagonists, are analgesic. Moreover, the local administration of anesthetics, at concentrations such as those occurring after spinal or epidural anesthesia, inhibits the release of SP, this inhibition being non-competitive [8].

2. After binding to the NK-1 receptor, SP induces mitogenesis in tumor cells and exerts angiogenic activity, as well as inducing tumor cell migration. In fact, it has been reported that SP stimulates the migration of human breast carcinoma cells (MDA-MB-468), a prerequisite for invasion and metastasis [9, 10]. Moreover, SP exerts an antiapoptotic effect [7].
3. The presence of both SP [11] and NK-1 receptors in tumoral tissues, including breast carcinoma [10, 12, 13], has been demonstrated. This means that SP could act through an autocrine mechanism, through which SP is secreted from primary tumors. In addition, the peptide could also be released from peripheral nerve terminals.
4. Breast carcinoma cells express and release more SP and express more NK-1 receptors [13] than normal breast cells.
5. NK-1 receptor antagonists exert an antitumor action: (a) by inhibiting tumor cell proliferation in several tumor cell lines, including breast cancer cells [10, 13, 14]. NK-1 receptor antagonists induce cellular death by apoptosis [10, 14]; (b) by inhibiting tumor neoangiogenesis [15]; and (c) by inhibiting the migration of tumoral cells (e.g., breast carcinoma cells) [9, 16]. NK-1 receptor antagonists also block the mitogenic action exerted by SP on tumor cells.

The above data, among others, should lead us to reappraise about the role of the SP/NK-1 receptor system and anesthetics in tumor progression, angiogenesis, and in the incidence of invasion and metastasis. As mentioned, it has been reported that regional anesthesia and analgesia may help to attenuate the surgical stress response by inhibiting the release of SP from nerve fibers. Thus, according to the five key points indicated previously, the following question arises: Is such inhibition one of the causes for the increase in survival of patients receiving regional anesthesia before surgery for breast cancer in the report published by Exadaktylos et al. [1]? In this sense, SP could be one of the perioperative factors, suggested by Exadaktylos et al. [1], that increase tumor growth and spreading. Thus, by inhibiting the release of SP, this peptide could not induce the latter two actions. If this were indeed the cause, might the risk of recurrence be further reduced by administering the drug aprepitant (which binds to the NK-1 receptor and after binding to such receptor induces apoptosis in several human tumoral cell lines [17]) as an adjunct NK-1 receptor antagonist in the perioperative period? This

binding induces all the beneficial effects that NK-1 receptor antagonists exert on the tumor growth and spreading, which are reported in the key-point 5. These questions require future investigation for confirmation, but the background that we have commented leads us to believe that it is quite possible that, as in pain and in neurogenic inflammation, in tumor progression, in angiogenesis and in tumor cell migration (invasion and metastasis), the activation of the NK-1 receptors by SP plays an important role, and hence the SP/NK-1 receptor system, after being blocked with NK-1 receptor antagonists/regional anesthesia, could be involved in the recurrence of cancers overexpressing NK-1 receptors. Thus, the results reported by Exadaktylos et al. [1] seem to be reliable and the cause might already be discovered, taking us to the dimension of Aristotle's concept of "techné".

References

1. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI (2006) Can anesthetics technique for primary breast cancer surgery affect recurrence of metastases? *Anesthesiology* 105:660–664
2. Kehlet H (1998) Modification of responses to surgery by neural blockade: clinical implications. In: Cousins M, Bridenbough M (eds) *Neural blockade in clinical anesthesia and pain management*. Lippincott-Raven, Philadelphia, pp 129–175
3. Ben-Eliyahu S (2002) The price of anticancer intervention. Does surgery promote metastasis? *Lancet Oncol* 3:578–579
4. Sacerdote P, Bianchi M, Gaspari L, Manfredi B, Maucione A, Terno G, Ammatuna M, Panerai AE (2000) The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. *Anesth Analg* 90:1411–1414
5. Yeager MP, Collacchio TA, Yu CT, Hildebrandt L, Howell AL, Weiss J, Guyre PM (1995) Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. *Anesthesiology* 83:500–508
6. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP (2002) Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signalling and promotes breast tumor growth. *Cancer Res* 62:4491–4498
7. Muñoz M, Rosso M, Coveñas R (2010) A new frontier in the treatment of cancer: NK-1 receptor antagonists. *Curr Med Chem* 17:504–513
8. Li YM, Wingrov DE, Too HP, Marnerakis M, Stimson ER, Strichartz GR, Maggio JE (1995) Local anesthetics inhibit substance P binding and evoked increases in intracellular Ca^{2+} . *Anesthesiology* 82:166–173
9. Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. *Int J Cancer* 112:231–238
10. Muñoz M, Rosso M, Aguilar FJ, González-Moles MA, Redondo M, Esteban F (2007) NK-1 receptor antagonists induce apoptosis and counteract substance p-related mitogenesis in human laryngeal cancer cell line HEP-2. *Invest New Drugs* 26:111–118
11. Khare VK, Albino AP, Reed JA (1998) The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions. *J Cutan Pathol* 25:2–10

12. Hennig IM, Laissue JA, Horisberger U, Reubi JC (1995) Substance-P receptors in human primary neoplasms: tumoral and vascular localization. *Int J Cancer* 61:786–792
13. Singh D, Joshi DD, Hameed M, Qian J, Gascón P, Maloof PB, Mosenthal A, Rameshwar P (2000) Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: Implications for bone marrow metastasis. *Proc Natl Acad Sci USA* 97:1388–1393
14. Muñoz M, Rosso M, Coveñas R, Montero I, González-Moles MA, Robles MJ (2007) Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732, 138. *Invest Ophthalmol Vis Sci* 48:2775–2781
15. Guha S, Eibl G, Kisfalvi K, Fan RS, Burdick M, Reber H, Hines OJ, Strieter R, Rozengurt E (2005) Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1, DTrp5, 7, 9, Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. *Cancer Res* 65:2738–2745
16. Meshki J, Douglas SD, Lai JP, Schwartz L, Kilpatrick LE, Tuluc F (2009) Neurokinin 1-receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism. *J Biol Chem* 284:9280–9289
17. Muñoz M, Rosso M (2009) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. *Invest New Drugs* 28:187–193